EP Patent

EP3820873A1 — Selective estrogen receptor degraders

Assigned to Eli Lilly and Co · Expires 2021-05-19 · 5y expired

What this patent protects

Novel selective estrogen receptor degraders (SERDs) according to the formula:, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, wherein either R 1 or R 2 is independently selected from Cl, F, -CF 3 , or -CH 3 , and the other is hydrogen, and m…

USPTO Abstract

Novel selective estrogen receptor degraders (SERDs) according to the formula:, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, wherein either R 1 or R 2 is independently selected from Cl, F, -CF 3 , or -CH 3 , and the other is hydrogen, and methods for their use are provided.

Drugs covered by this patent

Patent Metadata

Patent number
EP3820873A1
Jurisdiction
EP
Classification
—
Expires
2021-05-19
Drug substance claim
No
Drug product claim
No
Assignee
Eli Lilly and Co
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.